Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Entinostat in Relapsed and Refractory Lymphomas
NCT03179930Phase 2Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jun 2017
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of entinostat in classical Hodgkin lymphoma (cHL), sponsored by Memorial Sloan Kettering Cancer Center. Started Jun 2017; status: active, not recruiting.
02
Drugs
entinostat
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NCT03179930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03179930.